0001213900-25-098577 Sample Contracts
EXXEL PHARMA INC. COMMON STOCK PURCHASE WARRANTWarrant Agreement • October 14th, 2025 • Exxel Pharma, INC. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received John Nash or his assigns (“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of the consummation the first Liquidity Event (as defined below) occurring after the Original Issue Date of this Warrant (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on third anniversary of the Initial Exercise Date (“Termination Date”) but not thereafter, to subscribe for and purchase from Exxel Pharma Inc., a corporation organized under the laws of the Province of British Columbia (“Company”), up to the Initial Warrant Number of Shares (as hereinafter defined) of Common Stock (as subject to adjustment hereunder, “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in section 2(b). A “Liquidity Event” shall mea
Exxel Pharma Letterhead]Letter Agreement for Amendment to 12.5% Senior Secured Convertible Debenture and Replacement Warrant • October 14th, 2025 • Exxel Pharma, INC. • Pharmaceutical preparations • New York
This letter agreement (the “Amendment”) confirms the mutual agreement between Exxel Pharma, Inc., a Colorado corporation, with its principal place of business at 12635 E. Montview Blvd. Suite 114, Aurora, CO 80445, as successor in interest to Exxel Pharma Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the “Company”), and you, John Nash (the “Holder”), to amend certain terms of that certain 12.5% Senior Secured Convertible Debenture, dated November 20, 2024, in the original principal amount of $600,000.00 (the “Debenture”) and to confirm the replacement of the initially issued Common Stock Purchase Warrant as of November 20, 2024, with a newly issued Common Stock Purchase Warrant (the “Replacement Warrant”).
EXXEL PHARMA, INC. 20% CONVERTIBLE DEBENTUREConvertible Security Agreement • October 14th, 2025 • Exxel Pharma, INC. • Pharmaceutical preparations • New York
THIS 20% CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 20% Convertible Debentures of Exxel Pharma Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the “Company”), having its principal place of business at 12635 E. Montview Blvd., Suite 134, Aurora, CO 80045, designated as the Company’s 20% Convertible Debenture (this debenture, the “ Debenture “ and, collectively with the other debentures of such series, the “Debentures”).